DNA methylation alterations are early events in carcinogenesis and immune signalling in lung cancer. This study aimed to develop a model based on short stature homeobox 2 gene (SHOX2)/prostaglandin E receptor 4 gene (PTGER4) DNA methylation in plasma, appearance subtype of pulmonary nodules (PNs) and low-dose computed tomography (LDCT) images to distinguish early-stage lung cancers. We developed a multimodal prediction model with a training set of 257 individuals. The performance of the multimodal prediction model was further validated in an independent validation set of 42 subjects. In addition, we explored the association between SHOX2/PTGER4 DNA methylation and driver gene mutations in lung cancer based on data from The Cancer Genome Atlas (TCGA) portal. There were significant differences between the early-stage lung cancers and benign groups in the methylation levels. The area under a receiver operator characteristic curve (AUC) of SHOX2 in patients with solid nodules, mixed ground-glass opacity nodules and pure ground-glass opacity nodules were 0.693, 0.497 and 0.864, respectively, while the AUCs of PTGER4 were 0.559, 0.739 and 0.619, respectively. With the highest AUC of 0.894, the novel multimodal prediction model outperformed the Mayo Clinic model (0.519) and LDCT-based deep learning model (0.842) in the independent validation set. Database analysis demonstrated that patients with SHOX2/PTGER4 DNA hypermethylation were enriched in TP53 mutations. The present multimodal prediction model could more efficiently distinguish early-stage lung cancer from benign PNs. A prognostic index based on DNA methylation and lung cancer driver gene alterations may separate the patients into groups with good or poor prognosis.
Background: Intraductal carcinoma (IDC) and invasive cribriform (Cr) histologic patterns are important adverse morphologies in prostate cancer (PCa) and may influence pretreatment risk stratification. This study evaluated the feasibility of time-dependent diffusion magnetic resonance imaging (td-dMRI)-based microstructural mapping for preoperative characterization of these aggressive morphologies. Methods: This retrospective study included 95 men with pathologically confirmed PCa on radical prostatectomy specimens from March 2023 to March 2025. Td-dMRI was performed using pulsed and oscillating gradient diffusion sequences. Microstructural parameters, including extracellular diffusivity (Dex), cell diameter (d), intracellular volume fraction (fin), cellularity, and diffusivities at 0, 17, and 33 Hz (ADC0Hz, ADC17Hz, and ADC33Hz), were estimated using a two-compartment model. Conventional apparent diffusion coefficient (ADCDWI) values were obtained from standard diffusion-weighted imaging. Parameters were compared between tumors with and without Cr/IDC patterns, and diagnostic performance was assessed using receiver operating characteristic analysis. Pairwise comparisons of AUCs were performed using the DeLong test. Results: Among 95 participants, 62 (65.3%) had Cr/IDC patterns. Compared with Cr/IDC-negative tumors, Cr/IDC-positive tumors showed higher fin and cellularity (both p < 0.001) and lower ADCDWI, ADC0Hz, ADC17Hz, and ADC33Hz values (all p < 0.05). Dex and d did not differ significantly between groups. Among td-dMRI-derived parameters, fin showed the highest diagnostic performance (AUC = 0.757; 95% CI, 0.654–0.860). Conclusions: Td-dMRI-based microstructural mapping demonstrates promise for characterizing the Cr/IDC morphologies in PCa.
Background: Extensive-stage small cell lung cancer (ES-SCLC) is a rare yet highly aggressive malignancy with severely limited treatment options. The efficacy of immunotherapy for ES-SCLC remain limited, with only 14% of patients deriving additional benefit from immune checkpoint inhibitors (ICIs), underscoring significant heterogeneity in patient response. This study aimed to develop a model for the accurate prediction of prognosis and therapeutic response to optimize treatment strategies. Methods: 99 and 25 ES-SCLC patients were enrolled as training and independent internal validation cohorts. Baseline CT images, clinical data, and laboratory markers were collected. Prognostic factors were screened via Cox regression. A mediastinal window CT-based deep learning model (MWDL) was developed and combined with Progastrin-releasing peptide (log(ProGRP + 1)) and bone metastasis to establish the novel MWGB-Cox model. Results: ProGRP and bone metastasis were independent prognostic factors with area under the curves (AUCs) of 0.705 and 0.666 respectively for predicting 1-year OS. Among the pure deep learning models, the MWDL model achieved better performance with a mean AUC of 0.813 than the deep learning model based on lung window CT images (LWDL, AUC 0.756). Whereas the multimodal MWGB-Cox model not only achieved the highest AUC (0.902) for 1-year OS prediction, but also effectively overcame the limitation of insufficient sensitivity. The predictive performance of the MWGB-Cox model was further validated in the independent internal validation cohort. Conclusions: This novel, simple, and cost-effective multimodal MWGB-Cox model integrating CT-based deep learning, log(ProGRP + 1), and bone metastasis could robustly predict 1-year OS of ES-SCLC patients receiving first-line immunotherapy, providing a reliable tool for clinical decision-making. Significance: By integrating CT-based deep learning, log(ProGRP + 1) levels, and bone metastasis, the novel multimodal model achieved the highest predictive AUC (0.902) with improved sensitivity, serving as a simple, cost-effective tool for clinical decision-making.